SolveBio Funding: How Much Did They Raise & Key Investors

How Much Did SolveBio Raise?
Funding & Key Investors

SolveBio has successfully secured a major strategic investment, marking a pivotal moment in its trajectory within the translational medicine sector. With a total capital accumulation of $2M, the firm continues to solidify its market presence. This recent funding round, totaling $2M, underscores the confidence investors place in the company's ability to bridge the gap between complex biological data and actionable clinical insights.

The infusion of capital serves as a catalyst for SolveBio to accelerate its technological development, specifically targeting the harmonization of multi-omics data. By leveraging this financial backing, the company is well-positioned to expand its partnerships with global pharmaceutical and diagnostic organizations, ensuring that molecular knowledge is effectively integrated into therapeutic development pipelines.

What is SolveBio?

SolveBio

Software

Healthcare Software

Business Intelligence (BI) Software

Founded in 2013, SolveBio operates at the intersection of biotechnology and data science. The company provides a sophisticated platform designed to index, harmonize, and link disparate biological data sources in real-time. By enabling a collaborative, in-depth view of targets, biomarkers, and clinical trials, SolveBio empowers biotech and pharma entities to navigate the complexities of modern drug discovery. Its core technology acts as a critical infrastructure layer, transforming raw data into a strategic asset for precision medicine and diagnostic innovation.

How much funding has SolveBio raised?

SolveBio has raised a total of $2M across 1 funding round:

2014

Angel/Seed

$2M

Angel/Seed (2014): $2M with participation from SV Angel and Andreessen Horowitz

Key Investors in SolveBio

SV Angel

SV Angel is a long-term investment firm dedicated to supporting founders in creating impactful businesses through strategic insights and a vast network.

Andreessen Horowitz

Andreessen Horowitz is a prominent venture capital firm that invests in bold entrepreneurs building the future through technology.

What's next for SolveBio?

Looking ahead, SolveBio is poised to scale its enterprise-level operations, focusing on the integration of proprietary internal customer information with external biological datasets. The strategic roadmap involves deepening its footprint in the life sciences ecosystem, where the demand for real-time, high-fidelity data analytics is rapidly increasing. As the company matures, the focus will likely shift toward enhancing its predictive modeling capabilities and expanding its reach within the global clinical research market, ultimately driving more efficient therapeutic outcomes.

See full SolveBio company page

See More Financial Insights